Hemophilia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

NEW YORK, Sept. 19, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Hemophilia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0617097/Hemophilia-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Hemophilia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Hemophilia Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Hemophilia Therapeutics market. The report identifies the key trends shaping and driving the global Hemophilia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Hemophilia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Hemophilia Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Hemophilia Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Hemophilia Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Hemophilia Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Hemophilia Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Hemophilia Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Hemophilia Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Hemophilia Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 3

1.1 List of Tables 6

1.2 List of Figures 7

2 Hemophilia Therapeutics - Introduction 9

2.1 Disease Overview 9

2.2 Classification of Hemophilia and Other Bleeding Disorders 10

2.2.1 Classification of Hemophilia on the Basis of Coagulation Factor Deficiency 10

2.2.2 Classification of Hemophilia on the Basis of Bleeding Manifestations 10

2.2.3 Other Bleeding Disorders 11

2.3 Epidemiology 11

2.4 Etiology 12

2.5 Sign and Symptoms 12

2.6 Diagnosis 13

2.7 Treatment and Management of Hemophilia 13

2.7.1 Factor Concentrates 13

2.7.2 Whole Blood 18

2.7.3 Fresh Plasma 18

2.7.4 Desmopressin (DDAVP) 18

2.7.5 Antifibrinolytic agents 18

2.7.6 Inhibitors 18

2.7.7 Gene Therapy 20

2.7.8 Advantages and Disadvantages of Treatment Methods of Hemophilia 21

2.8 Management of Hemophilia 22

2.9 Acquired Hemophilia 22

2.9.1 Treatment of Acquired Hemophilia 22

2.10 GlobalData Pipeline Report Guidance 23

3 Hemophilia Therapeutics - Market Characterization 24

3.1 Hemophilia Therapeutics Market Size (2005-2010) - Global 24

3.2 Hemophilia Therapeutics Market Forecast (2010-2018) – Global 26

3.3 Hemophilia Therapeutics Market Size (2005-2010) - The US 29

3.4 Hemophilia Therapeutics Market Forecast (2010-2018) - The US 31

3.5 Hemophilia Therapeutics Market Size (2005-2010) - France 34

3.6 Hemophilia Therapeutics Market Forecast (2010-2018) - France 36

3.7 Hemophilia Therapeutics Market Size (2005-2010) - Germany 39

3.8 Hemophilia Therapeutics Market Forecast (2010-2018) - Germany 41

3.9 Hemophilia Therapeutics Market Size (2005-2010) - Italy 45

3.10 Hemophilia Therapeutics Market Forecast (2010-2018) - Italy 47

3.11 Hemophilia Therapeutics Market Size (2005-2010) - Spain 50

3.12 Hemophilia Therapeutics Market Forecast (2010-2018) - Spain 52

3.13 Hemophilia Therapeutics Market Size (2005-2010) - The UK 55

3.14 Hemophilia Therapeutics Market Forecast (2010-2018) - The UK 57

3.15 Hemophilia Therapeutics Market Size (2005-2010) - Japan 60

3.16 Hemophilia Therapeutics Market Forecast (2010-2018) - Japan 62

3.17 Drivers and Barriers for the Hemophilia Therapeutics Market 65

3.17.1 Drivers for the Hemophilia Therapeutics Market 65

3.17.2 Barriers for the Hemophilia Therapeutics Market 66

3.18 Opportunity and Unmet Need 66

3.18.1 Opportunity and Unmet Need for Hemophilia A 68

3.18.2 Opportunity and Unmet Need for Hemophilia B 69

3.18.3 Opportunity and Unmet Need for Hemophilia A and B Patients with Inhibitors 70

3.19 Key Takeaway 71

4 Hemophilia Therapeutics Market - Competitive Assessment 72

4.1 Hemophilia Therapeutics Market – Overview 72

4.2 Strategic Competitor Assessment 74

4.2.1 Competitor Assessment Within Different Therapeutic Categories Employed in Hemophilia Treatment 74

4.3 Product Profile for the Major Marketed Products in the Hemophilia Therapeutics Market 77

4.3.1 NovoSeven (Coagulation Factor VIIa) 77

4.3.2 Advate (Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method) 78

4.3.3 Kogenate FS (Antihemophilic Factor (Recombinant) Formulated with Sucrose) 78

4.3.4 XYNTHA (Antihemophilic Factor (Recombinant), Plasma/Albumin-Free) 79

4.3.5 BeneFIX (Coagulation Factor IX (Recombinant)) 80

4.3.6 Monoclate-P (Antihemophilic factor (human) Factor VIII: C pasteurized monoclonal antibody purified) 80

4.3.7 Mononine (Coagulation factor IX (human)) 81

4.3.8 FEIBA-VH (Anti-Inhibitor Coagulant Complex) 82

4.4 Key Takeaway 82

5 Hemophilia Therapeutics - Pipeline Assessment 83

5.1 Overview 83

5.2 Strategic Pipeline Assessment 83

5.3 Hemophilia Pipeline – Pipeline by Phases of Development 84

5.3.1 Hemophilia Therapeutics – Pre-registration 84

5.3.2 Hemophilia Therapeutics – Phase III Pipeline 85

5.3.3 Hemophilia Therapeutics – Phase II Pipeline 86

5.3.4 Hemophilia Therapeutics – Phase I/II Pipeline 86

5.3.5 Hemophilia Therapeutics – Phase I Pipeline 87

5.3.6 Hemophilia Therapeutics – Preclinical Pipeline 88

5.3.7 Hemophilia Therapeutics – Discovery Pipeline 89

5.4 Hemophilia Therapeutics – Pipeline by Mechanism of Action 90

5.5 Hemophilia Therapeutics – Pipeline by Therapeutic Class 91

5.5.1 Technology Trends Analytic Framework 92

5.6 Hemophilia Therapeutics – Promising Drugs under Clinical Development 93

5.7 Molecule Profile for Promising Drugs Under Clinical Development 94

5.7.1 NecLip-pdFVIII (LongAte) 94

5.7.2 Human-cl rhFVIII 94

5.7.3 NN7008 (recombinant factor VIII or rFVIII) 94

5.7.4 NN7999 (N9-GP, rFIX glycopegylated) 95

5.7.5 Kogenate PF (recombinant factor VIII, BAY81-8973) 96

5.7.6 Long Lasting rFactor VIII Fc Fusion Protein (rFVIIIFc) 97

5.7.7 Long Lasting rFactor IX Fc Fusion Protein (rFIXFc) 98

5.7.8 IB1001 (Recombinant Factor IX) 99

5.7.9 OBI-1 (rpFVIII) 99

5.7.10 BAX 326 100

5.7.11 FEIBA NF 100

5.7.12 Biostate 101

5.8 Key Takeaway 101

6 Hemophilia Therapeutics - Clinical Trials Mapping 102

6.1 Clinical Trials by Country (US, EU5 and Japan) 102

6.2 Clinical Trials by Phase 103

6.3 Clinical Trials by Status 104

6.4 Overall Sponsors 105

6.5 Prominent Sponsors 106

6.6 Top Companies Participating in Hemophilia Therapeutics Clinical Trials 107

7 Hemophilia Therapeutics - Strategic Assessment 108

7.1 Hemophilia Therapeutics: Implications for Future Market Competition 108

8 Hemophilia Therapeutics - Future Players 109

8.1 Introduction 109

8.2 Company Profiles 109

8.2.1 Baxter International Inc. 109

8.2.2 Recoly NV 111

8.2.3 Bayer AG 111

8.2.4 Novo Nordisk A/S 113

8.2.5 CSL Limited 114

8.2.6 Octapharma AG 115

8.2.7 Biogen Idec 117

8.2.8 Inspiration Biopharmaceuticals, Inc 118

8.2.9 Ipsen S.A. 119

8.2.10 Other Companies in the Hemophilia Therapeutics Market 120

9 Hemophilia Therapeutics - Licensing and Partnership Deals 124

10 Hemophilia Therapeutics - Appendix 129

10.1 Market Definitions 129

10.2 Abbreviations 129

10.3 Methodology 130

10.3.1 Coverage 130

10.3.2 Secondary Research 130

10.3.3 Forecasting 131

10.3.4 Primary Research 133

10.3.5 Expert Panel Validation 134

10.4 Contact Us 134

10.5 Disclaimer 134

10.6 Bibliography 134

List of Tables

Table 1: Bleeding Manifestations in Hemophilia 10

Table 2: Hemophilia, Patients Diagnosed in 2009 12

Table 3: Hematology Laboratory Tests 13

Table 4: Consumption Breakdown of Factor Concentrates 14

Table 5: Characteristics of Factor VIII Replacement Products 16

Table 6: Characteristics of Factor IX Replacement Products 17

Table 7: Characteristics of Bypassing Agents 19

Table 8: Hemophilia Therapeutics Market, Global, Revenue ($m), 2005–2010 26

Table 9: Hemophilia Therapeutics Market, Global, Forecast ($m), 2010–2018 28

Table 10: Hemophilia Therapeutics Market, The US, Revenue ($m), 2005–2010 31

Table 11: Hemophilia Therapeutics Market, The US, Forecast ($m), 2010–2018 33

Table 12: Hemophilia Therapeutics Market, France, Revenue ($m), 2005–2010 36

Table 13: Hemophilia Therapeutics Market, France, Forecast ($m), 2010–2018 38

Table 14: Hemophilia Therapeutics Market, Germany, Revenue ($m), 2005–2010 41

Table 15: Hemophilia Therapeutics Market, Germany, Forecast ($m), 2010–2018 44

Table 16: Hemophilia Therapeutics Market, Italy, Revenue ($m), 2005–2010 47

Table 17: Hemophilia Therapeutics Market, Italy, Forecast ($m), 2010–2018 49

Table 18: Hemophilia Therapeutics Market, Spain, Revenue ($m), 2005–2010 52

Table 19: Hemophilia Therapeutics Market, Spain, Forecast ($m), 2010–2018 54

Table 20: Hemophilia Therapeutics Market, The UK, Revenue ($m), 2005–2010 57

Table 21: Hemophilia Therapeutics Market, The UK, Forecast ($m), 2010–2018 60

Table 22: Hemophilia Therapeutics Market, Japan, Revenue ($m), 2005–2010 62

Table 23: Hemophilia Therapeutics Market, Japan, Forecast ($m), 2010–2018 64

Table 24: Major Brands - Usage in Hemophilia Therapeutics Market 72

Table 25: Approval and Launch Dates of Major Brands in Hemophilia Therapeutics Market 73

Table 26: Hemophilia Therapeutics – Pre-registration, 2011 84

Table 27: Hemophilia Therapeutics – Phase III Pipeline, 2011 85

Table 28: Hemophilia Therapeutics – Phase II Pipeline, 2011 86

Table 29: Hemophilia Therapeutics – Phase I/II Pipeline, 2011 86

Table 30: Hemophilia Therapeutics – Phase I Pipeline, 2011 87

Table 31: Hemophilia Therapeutics – Preclinical Pipeline, 2011 88

Table 32: Hemophilia Therapeutics – Discovery Pipeline, 2011 89

Table 33: Mechanism of Action for the 'Other' molecules in the Figure Above 90

Table 34: Hemophilia Therapeutics – Promising Drugs Under Clinical Development, 2011 93

Table 35: Hemophilia Therapeutics – Clinical Trials by Country, 2011 102

Table 36: Hemophilia Therapeutics – Clinical Trials by Phase, 2011 103

Table 37: Hemophilia Therapeutics – Clinical Trials by Status, 2011 104

Table 38: Hemophilia Therapeutics – Overall Sponsors, 2011 105

Table 39: Hemophilia Therapeutics –Prominent Sponsors, 2011 106

Table 40: Hemophilia Therapeutics: Top Companies Participating in Therapeutics Clinical Trials, 2011 107

Table 41: Baxter - Hemophilia Pipeline 2011 110

Table 42: Recoly NV - Hemophilia Pipeline 2011 111

Table 43: Bayer - Hemophilia pipeline 2011 112

Table 44: Novo Nordisk - Hemophilia Pipeline 2011 113

Table 45: CSL Limited - Hemophilia Pipeline 2011 115

Table 46: Octapharma AG - Hemophilia Pipeline 2011 116

Table 47: Biogen Idec. - Hemophilia Pipeline 2011 118

Table 48: Inspiration Biopharmaceuticals, Inc. - Hemophilia Pipeline 2011 118

Table 49: Ipsen SA - Hemophilia Pipeline 2011 120

Table 50: Hemophilia Therapeutics Market – Other Future Players, 2011 120

Table 51: Hemophilia Therapeutics, Licensing and Partnership Deals, 2011 124

List of Figures

Figure 1: The Coagulation Cascade 9

Figure 2: Patients Diagnosed in 2009 11

Figure 3: Proportional Usage of Plasma Versus Recombinant Factor VIII for Hemophilia A Patients Reported in WFH Survey 2009 14

Figure 4: Proportional Usage of Plasma Versus Recombinant Factor IX for Hemophilia B Patients Reported in WFH Survey 2009 15

Figure 5: Advantages and Disadvantages of Treatment Methods of Hemophilia 21

Figure 6: Key Aspects of Management of Hemophilia 22

Figure 7: Hemophilia A Therapeutics Market, Global, Revenue ($m), 2005-2010 24

Figure 8: Hemophilia B Therapeutics Market, Global, Revenue ($m), 2005-2010 25

Figure 9: Hemophilia Therapeutics (A&B), Global, Market Share (%), 2010 25

Figure 10: Hemophilia A Therapeutics Market, Global, Forecasts ($m), 2010-2018 27

Figure 11: Hemophilia B Therapeutics Market, Global, Forecasts ($m), 2010-2018 27

Figure 12: Hemophilia Therapeutics (A&B), Global, Market Share (%), 2018 28

Figure 13: Hemophilia A Therapeutics Market, The US, Revenue ($m), 2005-2010 29

Figure 14: Hemophilia B Therapeutics Market, The US, Revenue ($m), 2005-2010 30

Figure 15: Hemophilia Therapeutics (A&B), The US, Market Share (%), 2010 30

Figure 16: Hemophilia A Therapeutics Market, The US, Forecasts ($m), 2010-2018 32

Figure 17: Hemophilia B Therapeutics Market, The US, Forecasts ($m), 2010-2018 32

Figure 18: Hemophilia Therapeutics (A&B), The US, Market Share (%), 2018 33

Figure 19: Hemophilia A Therapeutics Market, France, Forecast ($m), 2005-2010 34

Figure 20: Hemophilia B Therapeutics Market, France, Revenue ($m), 2005-2010 35

Figure 21: Hemophilia Therapeutics (A&B), France, Market Share (%), 2010 35

Figure 22: Hemophilia A Therapeutics Market, France, Forecast ($m), 2010-2018 37

Figure 23: Hemophilia B Therapeutics Market, France, Forecast ($m), 2010-2018 37

Figure 24: Hemophilia Therapeutics (A&B), France, Market Share (%), 2018 38

Figure 25: Hemophilia A Therapeutics Market, Germany, Revenue ($m), 2005-2010 39

Figure 26: Hemophilia B Therapeutics Market, Germany, Revenue ($m), 2005-2010 40

Figure 27: Hemophilia Therapeutics (A&B), Germany, Market Share (%), 2010 40

Figure 28: Hemophilia A Therapeutics Market, Germany, Forecast ($m), 2010-2018 42

Figure 29: Hemophilia B Therapeutics Market, Germany, Forecast ($m), 2010-2018 43

Figure 30: Hemophilia Therapeutics (A&B), Germany, Market Share (%), 2018 43

Figure 31: Hemophilia A Therapeutics Market, Italy, Revenue ($m), 2005-2010 45

Figure 32: Hemophilia B Therapeutics Market, Italy, Revenue ($m), 2005-2010 46

Figure 33: Hemophilia Therapeutics (A&B), Italy, Market Share (%), 2010 46

Figure 34: Hemophilia A Therapeutics Market, Italy, Forecast ($m), 2010-2018 48

Figure 35: Hemophilia A Therapeutics Market, Italy, Forecast ($m), 2010-2018 48

Figure 36: Hemophilia Therapeutics (A&B), Italy, Market Share (%), 2018 49

Figure 37: Hemophilia A Therapeutics Market, Spain, Revenue ($m), 2005-2010 50

Figure 38: Hemophilia B Therapeutics Market, Spain, Revenue ($m), 2005-2010 51

Figure 39: Hemophilia Therapeutics (A&B), Spain, Market Share (%), 2010 51

Figure 40: Hemophilia A Therapeutics Market, Spain, Forecast ($m), 2010-2018 53

Figure 41: Hemophilia B Therapeutics Market, Spain, Forecast ($m), 2010-2018 53

Figure 42: Hemophilia Therapeutics (A&B), Spain, Market Share (%), 2018 54

Figure 43: Hemophilia A Therapeutics Market, The UK, Revenue ($m), 2005-2010 55

Figure 44: Hemophilia B Therapeutics Market, The UK, Revenue ($m), 2005-2010 56

Figure 45: Hemophilia Therapeutics (A&B), The UK, Market Share (%), 2010 56

Figure 46: Hemophilia A Therapeutics Market, The UK, Forecast ($m), 2010-2018 58

Figure 47: Hemophilia B Therapeutics Market, The UK, Forecast ($m), 2010-2018 59

Figure 48: Hemophilia Therapeutics (A&B), The UK, Market Share (%), 2018 59

Figure 49: Hemophilia A Therapeutics Market, Japan, Revenue ($m), 2005-2010 60

Figure 50: Hemophilia B Therapeutics Market, Japan, Revenue ($m), 2005-2010 61

Figure 51: Hemophilia Therapeutics (A&B), Japan, Market Share (%), 2010 61

Figure 52: Hemophilia A Therapeutics Market, Japan, Forecast ($m), 2010-2018 63

Figure 53: Hemophilia B Therapeutics Market, Japan, Forecast ($m), 2010-2018 63

Figure 54: Hemophilia Therapeutics (A&B), Japan, Market Share (%), 2018 64

Figure 55: Hemophilia Market, Drivers and Barriers, 2011 66

Figure 56: Opportunity and Unmet Need for Hemophilia A Therapeutics Market, 2011 68

Figure 57: Opportunity and Unmet Need for Hemophilia B Therapeutics Market, 2011 69

Figure 58: Opportunity and Unmet Need for Hemophilia A&B Inhibitors Therapeutics Market, 2011 70

Figure 59: Hemophilia A Therapeutics – Strategic Competitor Assessment, 2011 74

Figure 60: Hemophilia B Therapeutics – Strategic Competitor Assessment, 2011 75

Figure 61: Hemophilia A and B with Inhibitors Therapeutics, 2011 76

Figure 62: Hemophilia Therapeutics – Pipeline by Phase of Development, 2011 84

Figure 63: Hemophilia Therapeutics – Clinical Pipeline by Mechanism Of Action, 2011 90

Figure 64: Hemophilia Therapeutics – Clinical Pipeline by Therapeutic Class, 2011 91

Figure 65: Hemophilia Therapeutics – Technology Trends Analytics Framework, 2011 92

Figure 66: Hemophilia Therapeutics – Technology Trends Analytics Framework – Description, 2011 93

Figure 67: Hemophilia Therapeutics – Clinical Trials by Country, 2011 102

Figure 68: Hemophilia Therapeutics – Clinical Trials by Phase, 2011 103

Figure 69: Hemophilia Therapeutics – Clinical Trials by Status, 2011 104

Figure 70: Hemophilia Therapeutics – Overall Sponsors, 2011 105

Figure 71: Hemophilia Therapeutics – Prominent Sponsors, 2011 106

Figure 72: Hemophilia Therapeutics – Top Companies Participating in Clinical Trials, 2011 107

Figure 73: Implications for Future Market Competition in Hemophilia Therapeutics Market, 2011 108

Figure 74: Hemophilia – Pipeline by Company, 2011 109

Figure 75: GlobalData Market Forecasting Model 133

Companies Mentioned

Baxter International Inc.

Recoly NV

Bayer AG

Novo Nordisk A/S

CSL Limited

Octapharma AG

Biogen Idec

Inspiration Biopharmaceuticals, Inc

Ipsen S.A.

To order this report:

Pathology Industry: Hemophilia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Pathology Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Contact:

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker